Skip to main content

Table 2 Frequencies of founder mutations in distinct categories of ovarian cancer patients

From: High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients

Clinical variable

St.-Petersburg (n = 290)

Krasnodar (n = 64)

Age at onset (years)

  

   < 41

2/36 (5.6%)

1/1 (100.0%)

   41–60

22/172 (12.8%)

9/33 (27.2%)

   > 60

12/82 (14.6%)

2/30 (6.7%)

Non-informative

-

 

Family history*

  

   Positive

1/9 (11.1%)

-

   Negative

33/266 (12.4%)

-

   Non-informative

2/15 (13.3%)

12/64 (18.8%)

T status

  

   T1

2/52 (3.8%)

3/10 (30.0%)

   T>1

32/220 (14.5%)

8/53 (15.1%)

   Non-informative

2/18 (11.1%)

1/1 (100.0%)

N status

  

   N0

12/109 (11.0%)

1/4 (25.0%)

   N1

7/53 (13.2%)

1/1 (100.0%)

   N2

1/1 (100.0%)

-

   Non-informative

16/127 (12.6%)

10/59 (16.9%)

M status

  

   M0

22/186 (11.8%)

11/58 (19.0%)

   M1

6/63 (9.5%)

0/4 (0.0%)

   Non-informative

8/41 (19.5%)

1/2 (50.0%)

Tumor grade

  

   1–2

7/96 (7.3%)

9/48 (18.8%)

   3

23/154 (14.9%)

3/16 (18.8%)

   Non-informative

6/40 (15.0%)

-

Tumor histology

  

   Serous adenocarcinoma

36/250 (14.4%)

7/41 (17.1%)

   Mucinous adenocarcinoma

0/9 (0.0%)

0/2 (0.0%)

   Adenocarcinoma, not otherwise specified

0/16 (0.0%)

3/11 (27.3%)

   Other

0/15 (0.0%)

2/10 (20.0%)

  1. *Family history was defined as the presence of breast and/or ovarian cancer in mother or sister.